RA Capital Management’s Climb Bio CLYM Stock Holding History

RA Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$77.4M	Buy	11,300,939 +7,111	+0.1%	+$41K	0.82%	28
2025 Q4	$77.7M	Sell	11,293,828 -20,125,439	-64%	-$48.3M	0.8%	25
2025 Q3	$63.2M	Hold	31,419,267	–	–	0.78%	29
2025 Q2	$39M	Hold	31,419,267	–	–	0.66%	30
2025 Q1	$38.3M	Hold	31,419,267	–	–	0.64%	28
2024 Q4	$56.6M	Hold	31,419,267	–	–	0.75%	28
2024 Q3	$160M	Hold	31,419,267	–	–	1.84%	14
2024 Q2	$223M	Buy	31,419,267 +18,268,418	+139%	+$122M	2.95%	7
2024 Q1	$36M	Hold	13,150,849	–	–	0.46%	48
2023 Q4	$35.5M	Hold	13,150,849	–	–	0.55%	37
2023 Q3	$34.6M	Hold	13,150,849	–	–	0.68%	40
2023 Q2	$36.8M	Hold	13,150,849	–	–	0.7%	38
2023 Q1	$38.1M	Hold	13,150,849	–	–	0.86%	35
2022 Q4	$48.3M	Hold	13,150,849	–	–	0.98%	30
2022 Q3	$42.5M	Hold	13,150,849	–	–	0.91%	37
2022 Q2	$39.7M	Hold	13,150,849	–	–	1.06%	31
2022 Q1	$110M	Hold	13,150,849	–	–	2.41%	9
2021 Q4	$138M	Hold	13,150,849	–	–	2.43%	8
2021 Q3	$236M	Buy	+13,150,849	New	+$272M	3.28%	3

Other funds holding CLYM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

RA Capital Management's CLYM Position: Q1 2026 in Review

RA Capital Management increased its Climb Bio (CLYM) stake by 0.06% in Q1 2026, buying an estimated $41K and bringing the position to 11,300,939 shares worth $77.4M. The position accounts for 0.82% of the portfolio, ranked #28.

RA Capital Management first reported a position in CLYM in Q3 2021 and has held it in 19 quarters since. The position peaked at $236M in Q3 2021. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

RA Capital Management held 11,300,939 shares of Climb Bio worth $77.4M as of Q1 2026.
RA Capital Management bought 7,111 Climb Bio shares in Q1 2026, an estimated $41K.
Climb Bio made up 0.82% of RA Capital Management's portfolio in Q1 2026, its #28 holding.
RA Capital Management first reported a position in Climb Bio in Q3 2021 and has held it in 19 quarters since.
RA Capital Management's Climb Bio position peaked at $236M in Q3 2021.
80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.